阿达木单抗致结核文献分析

中国药物警戒 ›› 2018, Vol. 15 ›› Issue (11): 682-685.

• 安全性评价与合理用药 • 上一篇下一篇

阿达木单抗致结核文献分析

蔡俊¹, 卫菁², 纪立伟^{3, *}

1 南京大学医学院附属鼓楼医院,江苏南京 210008;
2 南京中医药大学附属江苏省中医院,江苏南京 210029;
3 北京医院药学部/国家老年医学中心,北京 100730

收稿日期:2019-01-09 修回日期:2019-01-09 出版日期:2018-11-20 发布日期:2019-01-09
通讯作者: 纪立伟,女,硕士,主任药师,临床药学与医院药物警戒。E-mail：jlw1228@sina.com
作者简介:蔡俊,男,硕士,主管药师,临床药学。

Literature Analysis of Tuberculosis Induced by Adalimumab

CAI Jun¹, WEI Jing², JI Liwei^{3, *}

1 Department of Pharmacy, Nanjing Drum Tower Hospital Affiliated to Medical College of Nanjing University, Jiangsu Nanjing 210008, China;
2 Jiangsu Province Hospital of TCM Affiliated to Nanjing University of Chinese Medicine, Jiangsu Nanjing 210029, China;
3 Beijing Hospital, National Center of Gerontology, Beijing 100730, China

Received:2019-01-09 Revised:2019-01-09 Online:2018-11-20 Published:2019-01-09

摘要/Abstract

摘要： 目的探究阿达木单抗致结核的一般规律和特点,为临床合理安全使用阿达木单抗提供参考。方法检索中国知网、万方、维普和Pubmed数据库截至2018年7月31日发表的使用阿达木单抗出现结核的文献,依据纳入与排除标准对文献资料进行提取与统计分析。结果共纳入39篇文献,共39例病例。男性患者与女性患者数量基本相当,40岁以上患者占比最多（79.49%）,原患疾病主要为类风湿关节炎（41.02%）,用药前结核筛查率为97.44%,肺外结核发生率为53.85%,94.87%的患者结核发病时间在用药后3年内,1例患者（2.56%）治疗无效死亡。结论加强对医务人员对阿达木单抗增加结核风险的关注,制定合理的随访计划,确保用药安全。

关键词: 阿达木单抗, 结核, 文献分析

Abstract: Objective To investigate the characteristics and patterns of tuberculosis induced by adalimumab, to find its risk factors and provide technical support for safe and rational use of drugs in clinic. Methods Literatures of tuberculosis induced by adalimumab published until July 2018 were retrieved from CNKI, Wanfang database, VIP Chinese full-text database and Pubmed. According to inclusion and exclusion criteria, the literatures were analyzed. Results A total of 39 papers, 39 cases were included. The proportion of tuberculosis occurring in men was almost the same as women. Patients aged over 40 years old had the highest percentage(79.49%), and the primary disease was rheumatoid arthritis (41.02%). The rate of tuberculosis screening before medication was 97.44%. The incidence of extrapulmonary tuberculosis was 53.85%. 94.87% patients suffered tuberculosis within 3 years after drug use. One patient (2.56%) died. Conclusion Attention of medical staff should be paid to the risk of tuberculosis induced by adalimumab, and the rational follow-up should be made to ensure the safe drug use in clinic.

Key words: adalimumab, tuberculosis, literature analysis

中图分类号:

R994.11

蔡俊, 卫菁, 纪立伟. 阿达木单抗致结核文献分析[J]. 中国药物警戒, 2018, 15(11): 682-685.

CAI Jun, WEI Jing, JI Liwei. Literature Analysis of Tuberculosis Induced by Adalimumab[J]. Chinese Journal of Pharmacovigilance, 2018, 15(11): 682-685.

参考文献

[1] 周兰兰,丁玉. 不同类型TNF拮抗剂治疗强直性脊柱炎发生不良反应的临床分析[J]. 上海交通大学学报(医学版), 2013,33(12):1620-1624.
[2] 范晓蕾,刘中华,岳涛,等. 血清TNF-α、IL-1β、IL-6和IL-17表达水平在阿达木单抗治疗活动性类风湿关节炎中的疗效预测作用[J].中国医科大学学报, 2018,47(6):556-561.
[3] 商瑜,何碧溪,常虹,等. 自身免疫性药物阿达木单抗在中国的发展现状[J]. 北京师范大学学报(自然科学版), 2015,51(6):591-594.
[4] Eng G P, Bouchelouche P, Bartels E M, et al.Anti-drug antibodies, drug levels, interleukin-6 and soluble TNF receptors in rheumatoid arthritis patients during the first 6 months of treatment with adalimumab or infliximab:a descriptive cohort study[J]. PLoS One,2016,11(9):e0162316.
[5] 张挺,李永吉,朱小春. 肿瘤坏死因子拮抗剂在类风湿关节炎中的应用进展[J]. 实用医学杂志, 2012,28(4):523-525.
[6] 王黎霞,成诗明,陈明亭,等. 2010年全国第五次结核病流行病学抽样调查报告[J]. 中国防痨杂志, 2012,34(8):485-508.
[7] Fina-Aviles F, Medina-Peralta M, Mendez-Boo L, et al.The descriptive epidemiology of rheumatoid arthritis in Catalonia: a retrospective study using routinely collected data[J]. Clin Rheumatol, 2016, 35(3):751-757.
[8] 中国医学会风湿病学分会. 2018中国类风湿关节炎诊疗指南[J]. 中华内科杂志, 2018,57(4):242-251.
[9] Keane J, Gershon S, Wise R P, et al.Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α-Neutralizing Agent[J]. N Engl J Med, 2001,345(15):1098-1104.
[10] 肿瘤坏死因子拮抗剂应用中结核病预防与管理专家建议组. 肿瘤坏死因子拮抗剂应用中结核病预防与管理专家共识[J]. 中华风湿病学杂志, 2013,17(8):508-513.
[11] Wang L, Turner M O, Elwood R K, et a1. A meta-analysis of the ffect of Bacille Calmette Guerin vaccination on tuberculin skin est measurements[J]. Thorax, 2002,57(9):804-809.
[12] Ponce de León D, Acevedo-Vásquez E, Sánchez-Torres A, et a1. Attenuated response to purified protein derivative in patients with rheumatoid arthritis: study in a population with a high prevalence of tuberculosis[J]. Ann Rheum Dis, 2005,64(9):1360-1361.
[13] Abubakar I, Stagg H R, Whitworth H, et al.How should I interpret an interferon gamma release assay result for tuberculosis infection?[J]. Thorax, 2013,68(3):298-301.
[14] Winthrop K L, Weinblatt M E, Daley C L.You can't always get what you want, but if you try sometimes (with two tests-TST and IGRA-for tuberculosis) you get what you need[J]. Ann Rheum Dis, 2012,71(11):1757-1760.
[15] Pinto L M, Grenier J, Schumacher S G, et al.Immunodiagnosis of Tuberculosis: State of the Art[J]. Med Princ Pract, 2012,21(1):4.
[16] 梁东风,张江林,黄烽. 肿瘤坏死因子-α拮抗剂引发结核二例分析并文献复习[J]. 中华风湿病学杂志, 2008,12(10):700-704.
[17] Ketata W, Rekik W K, Ayadi H, et al.Extrapulmonary tuberculosis[J]. Rev Pneumol Clin, 2015,71(2-3):83-92.
[18] 刘江,代倩,钟慕晓,等. 潜伏性结核感染在英夫利西治疗前的筛查[J]. 实用医学杂志, 2017,33(2):298-300.
[19] 李名石,任瑜,杨悦. 美国药品说明书管理研究[J]. 中国药物警戒, 2014, 11(12):739-742.
[20] Sen S, Peltz C, Jordan, et al. Infliximab-induced nonspecific interstitial pneumonia[J]. Am J Med Sci, 2012,344(1):75-78.

阿达木单抗致结核文献分析

Literature Analysis of Tuberculosis Induced by Adalimumab

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	陈超, 朱兰, 刘丽红, 韩佳寅, 朱彦. 文献来源的补骨脂及其制剂引起药物性肝损伤特点探析[J]. 中国药物警戒, 2023, 20(4): 449-453.
[2]	耿可欣, 张晓朦, 张冰, 林志健, 萨日娜, 姜皓, 邹丽娜. 哺乳期妇女应用中药安全问题分析与警戒[J]. 中国药物警戒, 2022, 19(8): 908-912.
[3]	任娱亲, 李歆, 余敏, 苏钰文. 基于OpenFDA的利妥昔单抗和阿达木单抗安全性评价与比较分析[J]. 中国药物警戒, 2022, 19(7): 752-756.
[4]	孙宝, 白延宁, 张媛媛, 乔逸, 杨志福, 王婧雯, 文爱东. 达托霉素致嗜酸粒细胞性肺炎的文献分析[J]. 中国药物警戒, 2022, 19(7): 757-761.
[5]	张瑞丽, 苏爽, 蒋季明, 张婧. 新癀片致药品不良反应分析[J]. 中国药物警戒, 2022, 19(5): 561-563.
[6]	黄丽, 魏龙, 李何美, 易丹. 58例氟比洛芬不良反应文献分析[J]. 中国药物警戒, 2022, 19(4): 436-440.
[7]	任全霞, 吴彬, 黄明霞. 利福平致急性肾损伤1例分析[J]. 中国药物警戒, 2022, 19(4): 453-455.
[8]	杨少杰, 夏玉朝, 任鹏飞, 王杰, 陈裕. 153例利奈唑胺致耐药结核病患者神经系统不良反应分析[J]. 中国药物警戒, 2022, 19(11): 1246-1249.
[9]	于一, 黄倩倩, 肖爱丽. 银杏叶片等口服制剂安全性风险的分析及思考[J]. 中国药物警戒, 2021, 18(7): 678-682.
[10]	解燕, 边原, 杜姗. 心元胶囊致重度肝损伤1例及文献分析[J]. 中国药物警戒, 2021, 18(4): 361-364.
[11]	胡叶敏, 刘芳. 再次暴露“乙胺吡嗪利福异烟片”致急性肾衰竭1例分析[J]. 中国药物警戒, 2021, 18(4): 384-387.
[12]	赵泽青, 王瑞, 于盼盼, 乔平平. 奥氮平临床不良反应文献分析[J]. 中国药物警戒, 2021, 18(3): 260-264.
[13]	夏霖, 杨弘雯, 王芳. 阿替卡因口腔科用药致药品不良反应文献分析[J]. 中国药物警戒, 2021, 18(2): 160-163.
[14]	于一, 王慧, 刘红亮, 王春婷. 注射用七叶皂苷钠安全性风险分析及思考[J]. 中国药物警戒, 2021, 18(2): 174-177.
[15]	高晓华. 178例盐酸羟考酮药品不良反应文献分析[J]. 中国药物警戒, 2021, 18(1): 72-76.